8-K: Reviva Pharmaceuticals Reports Q3 2024 Results and Provides Clinical Program Update

Reviva Pharmaceuticals announced its third quarter 2024 financial results, highlighted clinical progress with its brilaroxazine program, and provided an update on key milestones.

Summary

• Reviva Pharmaceuticals reported a net loss of $8.4 million, or $0.25 per share, for the third quarter of 2024, compared to a net loss of $11.3 million, or $0.48 per share, for the same period in 2023.
• The company's net loss for the first nine months of 2024 was $23.7 million, or $0.75 per share, compared to a net loss of $29.9 million, or $1.32 per share, for the same period in 2023.
• As of September 30, 2024, Reviva had $5.6 million in cash, a decrease from $23.4 million at the end of 2023.
• The company's 1-year open-label extension (OLE) trial for brilaroxazine has 108 patients who have completed one year of treatment, with over 250 patients completing six months of treatment.
• Topline data from the OLE trial is expected in December 2024, with full data analysis, including biomarker data, expected in the first quarter of 2025.
• Reviva is targeting a potential New Drug Application (NDA) submission for brilaroxazine in schizophrenia in the second quarter of 2026.
• The company presented positive vocal biomarker data from the Phase 3 RECOVER trial, reinforcing brilaroxazine's efficacy in treating negative symptoms of schizophrenia.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is positive clinical progress and reduced losses, the significant decrease in cash and the need for additional financing are concerning. The sentiment is cautiously optimistic.

Positives

• The company's net loss decreased year-over-year for both the quarter and the nine-month period.
• The brilaroxazine OLE trial is progressing well with a significant number of patients completing treatment milestones.
• Vocal biomarker data reinforces the efficacy of brilaroxazine.
• The company has a clear timeline for key milestones, including topline data, full data analysis, and NDA submission.
• Brilaroxazine has shown promise in treating multiple conditions, including schizophrenia, psoriasis, and pulmonary hypertension.

Negatives

• The company's cash balance has significantly decreased from $23.4 million to $5.6 million.
• The company is dependent on additional financing to initiate the Phase 3 RECOVER-2 trial.
• The company is still operating at a loss, although the losses are decreasing.

Risks

• The company's ability to raise sufficient funding is critical for the initiation of the Phase 3 RECOVER-2 trial.
• The company's cash burn rate is high, and the current cash balance may not be sufficient to fund operations until the targeted NDA submission in 2026.
• Clinical trial results may not be as positive as anticipated, which could delay or prevent regulatory approval.
• The company faces competition from other pharmaceutical companies developing treatments for similar conditions.
• Regulatory approval timelines are uncertain and could be delayed.

Future Outlook

The company anticipates topline data from the 1-year OLE trial in December 2024, full data analysis in Q1 2025, and a potential NDA submission for brilaroxazine in schizophrenia in Q2 2026. They also plan to initiate the Phase 3 RECOVER-2 trial in Q1 2025, subject to additional financing, and submit an IND for a liposomal-gel formulation of brilaroxazine in psoriasis in 2025.

Management Comments

• We continue to advance our late-stage brilaroxazine program with initial focus in schizophrenia and expansion potential across indications driven by underlying disruption in serotonin signaling, said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva.
• Our global 1-year OLE trial is progressing well, and we have over 100 patients who have completed one year of treatment which is a requirement for New Drug Application (NDA) submission.
• We remain highly encouraged by the differentiated potential of once-daily brilaroxazine to address major unmet needs for patients with schizophrenia and are targeting a potential NDA submission for brilaroxazine in the second quarter of 2026.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly companies focused on central nervous system (CNS) disorders. The positive vocal biomarker data and progress in the OLE trial position Reviva as a potential competitor in the schizophrenia treatment market. The expansion into other indications like psoriasis and pulmonary hypertension also highlights the potential of brilaroxazine as a versatile therapeutic.

Comparison to Industry Standards

• The reported net loss per share of $0.25 for Q3 2024 is an improvement compared to the $0.48 loss per share in Q3 2023, indicating progress in controlling expenses, however, the company is still operating at a loss.
• The cash balance of $5.6 million is low for a late-stage pharmaceutical company, especially considering the planned Phase 3 trial and NDA submission, which typically require significant capital. This is a concern when compared to companies with more robust cash reserves.
• The 108 patients completing one year of treatment in the OLE trial is a positive sign, as it provides the long-term safety data required for NDA submission. This is comparable to other companies conducting similar trials.
• The targeted NDA submission in Q2 2026 is a typical timeline for a late-stage drug development program, but it is subject to successful trial outcomes and regulatory review.
• The positive vocal biomarker data is a unique aspect of Reviva's program and could differentiate brilaroxazine from other schizophrenia treatments. This is a positive development compared to companies that rely solely on traditional symptom scales.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and the progress of its clinical programs.
• Employees will be impacted by the company's ability to secure funding and continue operations.
• Patients with schizophrenia and other conditions may benefit from the development of brilaroxazine.
• Creditors will be impacted by the company's financial stability and ability to repay debts.

Next Steps

• The company will release topline data from the 1-year OLE trial in December 2024.
• The company will complete a full data analysis of the OLE trial in Q1 2025.
• The company plans to initiate the Phase 3 RECOVER-2 trial in Q1 2025, subject to additional financing.
• The company plans to submit an IND for a liposomal-gel formulation of brilaroxazine in psoriasis in 2025.
• The company is targeting a potential NDA submission for brilaroxazine in schizophrenia in Q2 2026.

Key Dates

Keywords

brilaroxazine, schizophrenia, clinical trial, biomarker, NDA, open-label extension, RECOVER trial, pharmaceutical, CNS, net loss, financing, regulatory, psoriasis, pulmonary hypertension